. 2023 Sep 26;131(9):097009. doi: 10.1289/EHP11811

Table 5.

Effect estimates from regression analyses to determine the association of BMIz with hormone concentrations for the girls from Greater Cincinnati, 2004–2014.

	Six months before thelarche				Thelarche				Six months after thelarche				Twelve months after thelarche
	$N$	$β$	SE ( $β$ )	$p$ -Value	$N$	$β$	SE (β)	$p$ -Value	$N$	$β$	SE (β)	$p$ -Value	$N$	$β$	SE ( $β$ )	$p$ -Value
Estradiol	207	$negative 0.12$	0.05	0.02	205	$negative 0.10$	0.06	0.11	223	$negative 0.31$	0.06	$less than 0.01$	125	$negative 0.46$	0.09	$less than 0.01$
Estrone	208	$negative 0.09$	0.03	$less than 0.01$	186	$negative 0.12$	0.04	$less than 0.01$	224	$negative 0.16$	0.04	$< 0.01$	125	$negative 0.16$	0.06	$less than 0.01$
Testosterone	206	$negative 0.06$	0.04	0.08	190	$negative 0.06$	0.04	0.11	241	$negative 0.10$	0.04	$less than 0.01$	142	$negative 0.09$	0.04	0.05
DHEAS	221	$negative 0.05$	0.05	0.28	197	$negative 0.06$	0.05	0.27	250	$negative 0.04$	0.04	0.36	141	0.02	0.05	0.68

Note: All models were controlled for race and PFOA. Six months prior to thelarche was defined as 9 months prior to $less than to 3$ months prior to thelarche. Thelarche defined as 3 months prior to $less than 3$ months after thelarche. Six months after thelarche was defined as 3 months after thelarche to $less than 9$ months after thelarche. Twelve months after thelarche was defined as 9 months after thelarche to $less than 15$ months after thelarche. Significant at $p$ -value $less than or equal to 0.05$ . BMIz, body mass index $z$ -score based on 2000 CDC tables; CDC, Centers for Disease Control and Prevention; DHEAS, dihydroandrostendione sulfate; SE, standard error.